Hospital Burden of All-Cause Pneumonia and Nonbacteremic Pneumococcal Pneumonia in Adults in France Between 2013 and 2019.
Ayman Sabra, Marie Bourgeois, Emmanuelle Blanc, Stephane Fievez, Jennifer Mo��si, Gwena��l Goussiaume, Magali Lemaitre, Laurence Watier, Nicolas Coulombel, Julien Tr��hony, Aurore Tricotel, Yasmine Baghdadi, Muriel S Fartoukh
Author Information
Ayman Sabra: Medical Affairs, Vaccines, Antivirals and Evidence Generation, Pfizer, Paris, France. ORCID
Marie Bourgeois: Vaccines Department, Pfizer, Paris, France.
Emmanuelle Blanc: Vaccines Department, Pfizer, Paris, France.
Stephane Fievez: Health and Value Department, Pfizer, Paris, France.
Jennifer Mo��si: Medical Affairs, Vaccines, Antivirals and Evidence Generation, Pfizer, Paris, France.
Gwena��l Goussiaume: Vaccines Department, Pfizer, Paris, France.
Magali Lemaitre: Real World Solutions, IQVIA, Courbevoie, France.
Laurence Watier: Epidemiology and modelling of antibacterial evasion, Institut Pasteur, Paris, France.
Nicolas Coulombel: Real World Solutions, IQVIA, Courbevoie, France.
Julien Tr��hony: Real World Solutions, IQVIA, Courbevoie, France.
Aurore Tricotel: Real World Solutions, IQVIA, Courbevoie, France.
Yasmine Baghdadi: Real World Solutions, IQVIA, Courbevoie, France.
Muriel S Fartoukh: Assistance Publique-H��pitaux de Paris, Sorbonne Universit��, Service de m��decine intensive r��animation, H��pital Tenon, Paris, France.
Background: Community-acquired pneumonia (CAP) is associated with significant morbidity and mortality. The study objective was to describe the hospital burden of pneumonia in the adult population in France. Methods: This retrospective study was conducted from the National Health Insurance Database. All hospitalizations for pneumonia (all-cause) between 2013 and 2019 were included. Different risk categories for patients were established based on pneumococcal vaccine recommendations by French health authorities. Results: A total of 2 199 240 episodes of CAP were registered over the study period (annual mean, 314 177 [standard deviation, 17 818.6]); 75% occurred in patients aged ���65 years, among whom 47% were not classified in the moderate- or high-risk categories recommended for French pneumococcal vaccination. The incidence of CAP increased with age (117.9, 395.3, and 1916.7 per 100 000 for the age groups 18-49, 50-64, and ���65 years, respectively, in 2019). Furthermore, being at risk of pneumococcal disease resulted in more severe outcomes, including longer episode duration (mean, 14 days in low-risk vs 17 days in high-risk patients) and higher risk of referral to critical care units (from 20% to 27%), of rehospitalization up to 180 days (from 39% to 67%), of in-hospital death (from 12% to 19%), and of 1-year mortality (from 26% to 49%). Conclusions: This study establishes the incidence of CAP in adults in France, describes the significant burden of disease, and highlights the need for better prevention policies.
